Experimental study of effects of Protankyra Bidentata anti-tumor factor on tumor growth

( views:357, downloads:0 )
Author:
SHEN Xian-rong(Naval Medical Research Institute,Shanghai 200433,China)
LUAN Jie(Naval Medical Research Institute,Shanghai 200433,China)
JIANG Ding-wen(Naval Medical Research Institute,Shanghai 200433,China)
CHEN Wei(Naval Medical Research Institute,Shanghai 200433,China)
LU Li-na(Naval Medical Research Institute,Shanghai 200433,China)
LU Min(Naval Medical Research Institute,Shanghai 200433,China)
JIA Fu-xing(Naval Medical Research Institute,Shanghai 200433,China)
Journal Title:
CHINESE JOURNAL OF NAUTICAL MEDICINE AND HYPERBARIC MEDICINE
Issue:
Volume 15, Issue 04, 2008
DOI:
Key Word:
Protankyra Bidentata;Lung cancer;Liver cancer;Sarcoma;Tumor therapy

Abstract: Objective To study the inhibitory effects of Protankyra Bidentata anti-tumor factor(PBATF)on the growth of tumors implanted in mice or rats.Methods Methods of H22 liver cancer implanted in Kunming mice,Walker-256 sarcoma implanted in Wistar rats,human LAX lung cancer and human QGY liver cancer implanted in nest mice were used to detect the inhibitory effects of PBATF on the tumor growth,respectively.Animals in each model were divided into 5 groups:hish PBATF group(5 mg/kg),middle PBATF group(1 mg/kg),low PBATF group(0.5 mg/kg),positive control group(CTX)and negative control group.The preparations were administrated once a day,for 7-10 days.The LD50 peritoneal injection of PBATF was detected according to ordinary method.Results The inhibitory tumor rates of PBATF on Walker-256 sarcoma implanted in Wistar rats,human LAX lung caner implanted in nest mice,human QGY liver cancer implanted in nest mice and QGY liver cancer implanted in nest mice were 62.63%,56.02%,52.07% and 59.25% in high dose group,52.31%,50.60%,45.56% and 57.74% in middle dose group,37.49%,40.36%,33.14% and 45.28% in low dose group,respectively.The LD50 peritoneal injection of PBATF was 1.973 g/kg.Conclusions PBATF hag significant inhibitory effect on tumor growth in vivo.

  • [1]马天舒.葛迎春.海参活性物质的药理研究进展.特产研究,2003,(1):57-61.
  • [2]王衡文,程立.实验肿瘤学基础.北京:人民卫生出版社,1992:296-297.
  • [3]王强基,李春艳.玉足海参粘多糖对小鼠免疫功能的影响.海洋药物,1984,11:12-15.
  • [4]王振立,刘贵敏,郑瑞,等.刺参酸性粘多糖抑制小鼠肿瘤细胞DNA合成及其代谢研究.中国医药工业杂志,1993,24:405-408.
  • [5]苏秀榕,娄永江,常亚青,等.海参的营养成分及海参多糖的抗肿瘤活性的研究.营养学报,2003,25:181-182.
  • [6]陈正明,陈玉强,曹顺达,等.二色桌片参酶解液对转化细胞的效应.台湾海峡,1997,16:270-273.
  • [7]陈正明,陈清西,郑文竹,等.二色桌片参酶解液主要营养成分及抗癌作用的初步研究.海洋通报,1998,17:34-39.
  • [8]陈粤,苏文金,吴萍茹,等.二色桌片参化学成分:二色桌片参特蛋白抗肿瘤活性的研究.汕头大学医学院学报,2001,14:251-253.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn